Coronavirus Disease 2019: Coronaviruses and Blood Safety

Le Chang, Ying Yan, Lunan Wang, Le Chang, Ying Yan, Lunan Wang

Abstract

With the outbreak of unknown pneumonia in Wuhan, China, in December 2019, a new coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), aroused the attention of the entire world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). The World Health Organization declared COVID-19 in China as a Public Health Emergency of International Concern. Two other coronavirus infections-SARS in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012-both caused severe respiratory syndrome in humans. All 3 of these emerging infectious diseases leading to a global spread are caused by β-coronaviruses. Although coronaviruses usually infect the upper or lower respiratory tract, viral shedding in plasma or serum is common. Therefore, there is still a theoretical risk of transmission of coronaviruses through the transfusion of labile blood products. Because more and more asymptomatic infections are being found among COVID-19 cases, considerations of blood safety and coronaviruses have arisen especially in endemic areas. In this review, we detail current evidence and understanding of the transmission of SARS-CoV, MERS-CoV, and SARS-CoV-2 through blood products as of February 10, 2020, and also discuss pathogen inactivation methods on coronaviruses.

Keywords: 2019-nCoV; Blood safety; COVID-19; Coronavirus; MERS; Pathogen inactivation technology; SARS; SARS-CoV-2.

Copyright © 2020 Elsevier Inc. All rights reserved.

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020 doi: 10.1016/s0140-6736(20)30183-5.
    1. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, 2004 [accessed 2020-2-5].
    1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) 2013 [accessed 2020-2-5].
    1. Shan H., Zhang P. Viral attacks on the blood supply: the impact of severe acute respiratory syndrome in Beijing. Transfusion. 2004;44:467–469. .
    1. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976. .
    1. Grant P.R., Garson J.A., Tedder R.S., Chan P.K., Tam J.S., Sung J.J. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med. 2003;349:2468–2469. .
    1. Ng E.K., Hui D.S., Chan K.C., Hung E.C., Chiu R.W., Lee N. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem. 2003;49:1976–1980. .
    1. Ng E.K., Ng P.C., Hon K.L., Cheng W.T., Hung E.C., Chan K.C. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem. 2003;49:2085–2088. .
    1. Corman V.M., Albarrak A.M., Omrani A.S., Albarrak M.M., Farah M.E., Almasri M. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2016;62:477–483. .
    1. World Health Organization. WHO recommendations on SARS and blood safety, 2003 [accessed 2020-2-5].
    1. Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130–137. .
    1. Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020 doi: 10.1002/jmv.25681.
    1. Enjuanes L., Zuniga S., Castano-Rodriguez C., Gutierrez-Alvarez J., Canton J., Sola I. Molecular basis of coronavirus virulence and vaccine development. Adv Virus Res. 2016;96:245–286. .
    1. Ding Y., Wang H., Shen H., Li Z., Geng J., Han H. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200:282–289. .
    1. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523–534. .
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001017.
    1. Cheng P.K., Wong D.A., Tong L.K., Ip S.M., Lo A.C., Lau C.S. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004;363:1699–1700. .
    1. Hui D.S.C., Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33:869–889. .
    1. US Food and Drug Administration. Revised recommendations for the assessment of donor suitability and blood product safety in cases of suspected severe acute respiratory syndrome (SARS) or exposure to SARS: guidance for industry, 2003.
    1. Wang H., Mao Y., Ju L., Zhang J., Liu Z., Zhou X. Detection and monitoring of SARS coronavirus in the plasma and peripheral blood lymphocytes of patients with severe acute respiratory syndrome. Clin Chem. 2004;50:1237–1240. .
    1. Li L., Wo J., Shao J., Zhu H., Wu N., Li M. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. J Clin Virol. 2003;28:239–244. .
    1. Yilla M., Harcourt B.H., Hickman C.J., McGrew M., Tamin A., Goldsmith C.S. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res. 2005;107:93–101. .
    1. Law H.K., Cheung C.Y., Ng H.Y., Sia S.F., Chan Y.O., Luk W. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106:2366–2374. .
    1. Hung I.F., Cheng V.C., Wu A.K., Tang B.S., Chan K.H., Chu C.M. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10:1550–1557. .
    1. Poon T.C., Chan K.C., Ng P.C., Chiu R.W., Ang I.L., Tong Y.K. Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load. Clin Chem. 2004;50:1452–1455. .
    1. Schmidt M., Brixner V., Ruster B., Hourfar M.K., Drosten C., Preiser W. NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion. 2004;44:470–475. .
    1. Woo P.C., Lau S.K., Tsoi H.W., Chan K.H., Wong B.H., Che X.Y. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet. 2004;363:841–845. .
    1. Zhou Y.H. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet. 2004;363:1825–1826. author reply 6-7. .
    1. Young M. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet 2004;363: 1826; author reply -7. .
    1. Yip C.W., Hon C.C., Zeng F., Chow K.Y., Leung F.C. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet. 2004;363:1825. author reply 6-7. .
    1. Theron M. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet. 2004;363:1825. author reply 6-7. .
    1. Shang G., Biggerstaff B.J., Yang B., Shao C., Farrugia A. Theoretically estimated risk of severe acute respiratory syndrome transmission through blood transfusion during an epidemic in Shenzhen, Guangdong, China in 2003. Transfus Apher Sci. 2007;37:233–240. .
    1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. .
    1. Chafekar A., Fielding B.C. MERS-CoV: understanding the latest human coronavirus threat. Viruses. 2018;10 .
    1. American Association of Blood Banks. Middle East respiratory syndrome coronavirus, 2013 [accessed 2020-2-5].
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001316.
    1. Chan J.F., Yuan S., Kok K.H., To KK, Chu H., Yang J. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 doi: 10.1016/S0140-6736(20)30154-9.
    1. Phan L.T., Nguyen T.V., Luong Q.C., Nguyen T.V., Nguyen H.T., Le H.Q. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020 doi: 10.1056/NEJMc2001272.
    1. Rothe C., Schunk M., Sothmann P., Bretzel G., Froeschl G., Wallrauch C. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 doi: 10.1056/NEJMc2001468.
    1. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001191.
    1. Control Ecfdpa. Outbreak of acute respiratory syndrome associated with a novel coronavirus, Wuhan, China; first update, 2020 [accessed 2020-2-5].
    1. American Association of Blood Banks. Update: impact of 2019 novel coronavirus and blood safety, 2020 [accessed 2020-2-5].
    1. Rabenau H.F., Cinatl J., Morgenstern B., Bauer G., Preiser W., Doerr H.W. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol. 2005;194:1–6. .
    1. Lamarre A., Talbot P.J. Effect of pH and temperature on the infectivity of human coronavirus 229E. Can J Microbiol. 1989;35:972–974. .
    1. Eickmann M., Gravemann U., Handke W., Tolksdorf F., Reichenberg S., Muller T.H. Inactivation of three emerging viruses—severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus—in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. Vox Sang. 2020 doi: 10.1111/vox.12888.
    1. Hashem A.M., Hassan A.M., Tolah A.M., Alsaadi M.A., Abunada Q., Damanhouri G.A. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med. 2019;29:434–441. .
    1. Hindawi S.I., Hashem A.M., Damanhouri G.A., El-Kafrawy S.A., Tolah A.M., Hassan A.M. Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light. Transfusion. 2018;58:52–59. .
    1. Eickmann M., Gravemann U., Handke W., Tolksdorf F., Reichenberg S., Muller T.H. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion. 2018;58:2202–2207. .
    1. Darnell M.E., Taylor D.R. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion. 2006;46:1770–1777. .
    1. Rabenau HF, Biesert L, Schmidt T, Bauer G, Cinatl J, Doerr HW. SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation. Biologicals 2005;33: 95-9. .
    1. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion. 2005;45:580–590. .
    1. Yunoki M., Urayama T., Yamamoto I., Abe S., Ikuta K. Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. Vox Sang. 2004;87:302–303. .
    1. Leclercq I., Batejat C., Burguiere A.M., Manuguerra J.C. Heat inactivation of the Middle East respiratory syndrome coronavirus. Influenza Other Respir Viruses. 2014;8:585–586. .
    1. Keil S.D., Bowen R., Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion. 2016;56:2948–2952. .
    1. Rebulla P. The long and winding road to pathogen reduction of platelets, red blood cells and whole blood. Br J Haematol. 2019;186:655–667. .
    1. Seltsam A., Muller T.H. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol. 2013;162:442–454. .
    1. Chinese Society of Blood Transfusion. Recommendations on blood collection and supply during the epidemic of novel coronavirus pneumonia in China (1st edition) [Chinese], 2020 [accessed 2020-2-5].

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj